当前位置: X-MOL首页全球导师 国内导师 › 王绍祥

个人简介

深圳大学医学部,讲师,副研究员(2015年评定)。研究方向:细胞生物学、肿瘤药理学。主要从事食管癌干细胞中的抗肿瘤药理研究,已经成功建立食管癌耐药细胞模型、干细胞球模型、侧群细胞模型、化学诱导模型、裸鼠模型等,已申请6项第一发明人专利。作为项目负责人一共主持7个市级以上科研项目,包括国家自然基金青年基金(81201727),中国博士后基金面上项目(2012M511882)、中国博士后基金特别资助项目(2013T60827)、广东省自然基金项目(S2012040006873;C1730452100122)、深圳市科技计划项目(JCYJ20150324141711568;JCYJ20170302145059926),参与了“863”、国家自然基金面上项目等6个科研项目。近5年来,已经发表27篇SCI论文,其中14篇为第一作者或通讯作者。现为深圳大学医学部的青年教师,在实验技术、课题设计和实验室管理等方面积累了一定经验。在科研项目开展中统筹全局,包括人力安排、方案制定、技术攻关、文章撰写、项目汇报及结题等工作。 教育经历: 2008/9 - 2011/6,暨南大学,生物医药工程,博士,导师:王一飞 2006/9 - 2008/6,暨南大学,微生物与生化药学,硕士,导师:李体远 2001/9 - 2005/6,湘潭大学,制药工程,学士,导师:吴剑 工作经历: 2014/10 - 至今,深圳大学,医学部,副研究员 2011/10 - 2014/6,暨南大学,医学院,博士后 2005/6 - 2006/8,深圳市人民医院,中心实验室,实验员

研究领域

从事食管癌干细胞中的抗肿瘤药理研究

主持或参加科研项目(主持7个市级以上项目,主持项目总经费172万元) 1. (项目主持人)国家自然科学基金青年基金:内质网应激在SNX-2112诱导食管癌细胞死亡中的作用(81201727),起止时间:2013.01 – 2015.12,23万元; 2. (项目主持人)中国博士后科学基金特别资助:内质网应激抑制剂增强SNX-2112抗食管癌的作用机制(2013T60827),起止时间:2013.10 – 2014.10,15万元; 3. (项目主持人)中国博士后科学基金面上项目:内质网应激在SNX-2112诱导食管癌细胞死亡中的作用(2012M511882),起止时间:2012.01 – 2013.12,5万元; 4. (项目主持人)广东省自然科学基金博士启动项目:SNX-2112阻断内质网应激在食管癌细胞死亡中的作用(S2012040006873),起止时间:2012.10 – 2014.10,3万元; 5. (项目主持人)广东省省级科技计划项目:抑制IRE1增强食管癌干细胞药物敏感性的作用机制(c1730452100122),起止时间:2017.1.1 – 2018.12.31,30万元; 6. (项目主持人)深圳市科技计划项目:PERK/eIF2α通路调节食管癌化疗耐药的作用机制(JCYJ20170302145059926),起止时间:2017.06.01 - 2019.05.31,40万元; 7. (项目主持人)深圳市科技计划项目:内质网应激通路调控食管癌干细胞药物敏感性的作用机制(JCYJ20150324141711568),起止时间:2015.06.01 - 2017.08.31,30万元; 8. (项目主持人)暨南大学博士后科研项目资助:肿瘤分子靶点Hsp90调控食管癌发生发展的作用机理(55350014),起止时间:2014.01-2014.12,20万元; 9. (项目主持人)深圳大学新引进教师科研启动项目:调节 IRE1 在 Hsp90 抑制剂治疗食管癌中的作用机制(201572),起止时间:2015 年 06 月 至 2017 年 05 月,6万元; 10. (第二负责人)广州市科技计划项目:汉防己甲素(TET)及其衍生物克服人脑胶质瘤耐药的作用机制,起止时间:2014.01 – 2016.12,8万元; 11. (第三负责人)国家自然科学基金面上项目:植物糖基转移酶高表达工程菌减轻抗癌药伊立替康毒性研究 (81373496),起止时间:2014.1-2017.12,75万元; 12. (第三负责人)广州市珠江科技新星专项:植物糖基转移酶高表达工程菌减轻抗癌药伊立替康毒性研究,起止时间:2014.1-2016.12,30万元; 13. (第三负责人)学校培育基金,青年项目:基于靶标TrxR的新型四氢吲唑酮类化合物抗肿瘤作用机制及构效关系研究(21609303),2010.01-2010.12,2.5万; 14. (第四负责人)广东省自然科学基金青年基金:基于靶标TrxR的新型Mansonone F类似物抗宫颈癌作用机制研究(10451063201005506),2010.10-2012.09,5万; 15. (主要完成人)863项目:热休克蛋白(Hsp90)小分子靶向抑制剂及抗癌药物临床前研究(2007AA02Z142),起止时间:2007.06 – 2010.11,288万元(已优秀结题,该项目为博士生导师的科研项目,本人负责动物实验部分、项目的数据分析、各年年度汇报及结题报告的撰写)。 申请专利情况(共申请7项发明专利,其中6项为第一发明人) 王绍祥,王晓,王一飞,钟雪云,食管癌顺铂耐药性细胞株及其构建方法和应用,专利申请号:201511007006.2。 王绍祥,王绍其,王晓,王艳,王熙昊,常港,陈家杰,含PI3K抑制剂和PERK抑制剂的药物组合物及其应用,专利申请号:201710123267.3。 王绍祥,王绍其,王晓,陈家杰,常港,王艳,王熙昊,含索拉非尼和GSK2656157的药物组合物及用途,专利申请号:201710121670.2。 王绍祥,王晓,王一飞,胡超智,王绍其,徐海朋,含AKT抑制剂和IRE1抑制剂的药物组合物及其应用,专利申请号:201710135038.3。 王绍祥,王晓,王一飞,徐海朋,王绍其,胡超智,含有HDAC抑制剂和IRE1抑制剂的药物组合物及用途,专利申请号:201710121669.X。 王绍祥,钟雪云,张勇,王一飞,王晓,王绍其,一种治疗食管癌的药物组合物及用途,专利申请号:201710134282.8。 王晓,王绍祥,王一飞,钟雪云,王绍其,王熙昊,含Survivin抑制剂和IRE1抑制剂的药物及用途,专利申请号:201710135740.X。

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

发表学术论文情况(共发表27篇SCI论文,14篇为第一、通讯作者;注:#为第一、共同第一作者,*为通讯、共同作者) K.S. Liu, H. Liu, J.H. Qi, Q.Y. Liu, Z. Liu, M. Xia, G.W. Xing, S.X. Wang*(通讯), Y.F. Wang*, SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer letters 318 (2012) 180-188. (IF:6.375, Co-corresponding author) S.X. Wang#, Z. Du#, J. Luo, X. Wang, H. Li, Y. Liu, Y. Zhang, J. Ma, W. Xiao, Y. Wang*, X. Zhong*(通讯), Inhibition of heat shock protein 90 suppresses squamous carcinogenic progression in a mouse model of esophageal cancer. Journal of cancer research and clinical oncology (2015) Aug;141(8):1405-16. (IF:3.5024, First author) Y. Zhang, Y.L. Wen, J.W. Ma, J.C. Ye, X. Wang, J.X. Huang, C.Y. Meng, X.Z. Xu, S.X. Wang*, X.Y. Zhong, Tetrandrine inhibits glioma stem-like cells by repressing beta-catenin expression. International journal of oncology 50 (2017) 101-110. (IF:3.0789, Co-corresponding author) Y.T. Liu#, X. Wang#, Y. Wang, Y. Zhang, K. Zheng, H.Z. Yan, L. Zhang, W.B. Chen, X.Y. Wang, Q.Y. Liu, S.X. Wang*(通讯), Y.F. Wang*, Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells. International journal of oncology 46 (2015) 299-307. (IF:3.0789, Co-corresponding author) Y. Zhang#, S.X. Wang#, J.W. Ma, H.Y. Li, J.C. Ye, S.M. Xie, B. Du*, X.Y. Zhong*(通讯), EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. Journal of neuro-oncology 121 (2015) 41-52. (IF:3.0699, Co-first author) H.Q. Ju#, S.X. Wang#, Y.F. Xiang, Z. Liu, J.Y. Liu, Z.P. Chen, F.L. Zeng, M. Xia, Z.H. Liu, G.W. Xing, S.Y. Wang, Y.F. Wang*(通讯), BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. European journal of pharmacology 666 (2011) 26-34. (IF:2.8959, Co-first author) X. Wang#, S.X. Wang#, Y.T. Liu, D. Huang, K. Zheng, Y. Zhang, X.Y. Wang, Q.Y. Liu, D.P. Yang*, Y.F. Wang*(通讯), Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells. Oncology reports 33 (2015) 230-238. (IF:2.6619, Co-first author) Zhou X#, Wang S.X. #, Sun H, Wu B. (2015). "Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites." Drug Metab Pharmacokinet. (IF:2.568, Co-first author) Shao-Qi Wang, Xiao Wang, Kai Zheng, Kai-Sheng Liu, Shao-Xiang Wang*, Cong-Hua Xie. Simultaneous targeting PI3K and PERK pathways may obtain better treatment and improve the clinical prognosis in esophageal squamous carcinoma. Biochemical and biophysical research communications (2017年9月4日,online) . (IF: 2.4660, Co-corresponding author) S.X. Wang#, X. Wang#, Z. Du, Y.T. Liu, D.N. Huang, K. Zheng, K.S. Liu, Y. Zhang, X.Y. Zhong*, Y.F. Wang*(通讯), SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. Biochemical and biophysical research communications 450 (2014) 73-80. (IF:2.4660, First author) X. Wang#, S.X. Wang#, Y.T. Liu, W.C. Ding, K. Zheng, Y.F. Xiang, K.S. Liu, D.M. Wang, Y.Y. Zeng, M. Xia, D.P. Yang*, Y.F. Wang*(通讯), The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: The role of ER stress. Biochemical and biophysical research communications 446 (2014) 160-166. (IF: 2.4660, Co-first author) H. Li#, W. Xiao#, J. Ma, Y. Zhang, R. Li, J. Ye, X. Wang, X. Zhong*, S.X. Wang*(通讯), Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. International journal of clinical and experimental pathology 7 (2014) 7989-7998. (IF:1.7059, Co-corresponding author) Ru Li#, Haiying Li#, S.X. Wang#, Jiwei Ma, Yong Zhang, Jiecheng Ye, Yulin Wen, Xiao Wang, Xueyun Zhong, Weiwei Xiao. Novel prognostic value of nuclear lactate dehydrogenase-A in esophageal squamous cell carcinoma. 2016;9(3):3708-3716, International journal of clinical and experimental pathology (1936-2625) (IF: 1.7059, Co-first author) S.X. Wang#, H.Q. Ju#, K.S. Liu, J.X. Zhang, X. Wang, Y.F. Xiang, R. Wang, J.Y. Liu, Q.Y. Liu, M. Xia, G.W. Xing, Z. Liu*, Y.F. Wang*(通讯), SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Bioscience, biotechnology, and biochemistry 75 (2011) 1540-1545. (IF:1.2949, First author) 既非第一又非通讯作者的SCI论文 Zheng K, Li Y, S.X. Wang, Wang X, Liao C, Hu X, Fan L, Kang Q, Zeng Y, Wu X, Wu H, Zhang J, Wang Y, He Z. Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint. Autophagy (2016) Sep;12(9):1593-613. (IF:9.108) Z.J. Che#, S.X. Wang, S.G. Liu, G.B. Li, Q.T. Wu, C.Y. Lin, L.L. Kong, S. Wang*(通讯), Synthesis, structure, photoluminescence and antitumour activity of zinc complex based on 2-(2-(1H-benzo-[d]imidazol-2-yl)benzyl)-1H-benzo- [d]imidazole. Spectrochim Acta A 135 (2015) 878-882. (IF:2.192) G.B. Li#, S.X. Wang, W.Y. Su, R.K. Pan, K.D. Liu, S.G. Liu*(通讯), Synthesis, crystal structure, and antitumour activities of cobalt(II) complex based on 2,6-bis(1-phenylbenzimidazol-2-yl)pyridine. Russ J Coord Chem+ 40 (2014) 764-767. (IF:0.629) Y. Zhang#, H.X. Chen#, S.Y. Zhou, S.X. Wang, K. Zheng, D.D. Xu, Y.T. Liu, X.Y. Wang, X. Wang, H.Z. Yang, L. Zhang. Q.Y. Liu, W.Q. Chen, Y.F. Wang*(通讯), Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Molecular Cancer. (2015) DOI: 10.1186/s12943-015-0326-0. (IF:5.397) K.S. Liu#, Y. Zhang, W.C. Ding, S.X. Wang, Y.F. Xiang, P. Yang, Z.P. Chen, K. Zheng, Z. Liu, M. Xia, Y.F. Wang*(通讯), The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells. International journal of oncology 41 (2012) 2276-2284. (IF:2.773) K.S. Liu#, W.C. Ding, S.X. Wang, Z. Liu, G.W. Xing, Y. Wang, Y.F. Wang*(通讯), The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo. Oncology reports 27 (2012) 1904-1910. (IF:2.297) K. Zheng#, M.Y. Chen, Y.F. Xiang, K.Q. Ma, F.J. Jin, X. Wang, X.Y. Wang, S.X. Wang, Y.F. Wang*(通讯), Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. Biochemical and biophysical research communications 446 (2014) 990-996. (IF:2.595) Y.F. Xiang#, K. Zheng, M.G. Zhong, J. Chen, X. Wang, Q.L. Wang, S.X. Wang, Z. Ren, J.L. Fan, Y.F. Wang*(通讯), Ubiquitin-proteasome-dependent slingshot 1 downregulation in neuronal cells inactivates cofilin to facilitate HSV-1 replication. Virology 449 (2014) 88-95. (IF:3.367) R. Wang#, F.Y. Shao, Z. Liu, J.X. Zhang, S.X. Wang, J.Y. Liu, H. Liu, H.Y. Chen, K.S. Liu, M. Xia, Y.F. Wang*(通讯), The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-kappa B and disruption of mitochondria-dependent pathways. Chemico-biological interactions 205 (2013) 1-10. (IF:2.982) S.G. Liu#, W.Y. Su, R.K. Pan, X.P. Zhou, X.L. Wen, Y.Z. Chen, S.X. Wang, X.B. Shi*(通讯), The synthesis and luminescence of europium (III) complex based on deprotonated 1-(4-ethyl-4H-thieno[3,2-b]indol-6-yl)-4,4,4-trifluorobutane-1,3- dionate and 1,10-phenanthroline. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 103 (2013) 417-422. (IF:2.129) J.Y. Liu#, Z. Liu, D.M. Wang, M.M. Li, S.X. Wang, R. Wang, J.P. Chen, Y.F. Wang*, D.P. Yang*(通讯), Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chemico-biological interactions 190 (2011) 91-101. (IF:2.982) Y.F. Xiang#, K. Zheng, H.G. Ju, S.X. Wang, Y. Pei, W.C. Ding, Z.P. Chen, Q.L. Wang, X.X. Qiu, M.G. Zhong, F.L. Zeng, Z. Ren, C.W. Qian, G. Liu, K. Kitazato, Y.F. Wang*(通讯), Cofilin 1-Mediated Biphasic F-Actin Dynamics of Neuronal Cells Affect Herpes Simplex Virus 1 Infection and Replication. Journal of virology 86 (2012) 8440-8451. (IF:5.402) K. Zheng, Y.F. Xiang, X. Wang, Q.L. Wang, M.G. Zhong, S.X. Wang, X.Y. Wang, J.L. Fan, K. Kitazato, Y.F. Wang*(通讯), Epidermal Growth Factor Receptor-PI3K Signaling Controls Cofilin Activity To Facilitate Herpes Simplex Virus 1 Entry into Neuronal Cells. mBio 5 (2014). (IF:6.875)

推荐链接
down
wechat
bug